Global Blood Targeting
Location(s): United States
Global Blood Therapeutics' lead program focuses on Sickle Cell Disease (SCD), one of the earliest, rare genetic diseases to be defined on a molecular basis. It is caused by a single mutation that alters the oxygen-transport protein hemoglobin and results in the "sickling" – or change to a crescent shape – of red blood cells.
Global Blood Therapeutics' approach combines the most advanced approaches to computational biology and protein-ligand modeling with medicinal chemistry and empiric screening capabilities focused on allosteric modulation, while leveraging its team's world-leading expertise in blood biology and proven success in drug discovery and development.